681P OPTIM: A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck – AIO-KHT-0117

Abstract

While check point inhibitors (CPI) targeting PD-1 are a standard of care in recurrent or metastatic SCCHN (R/M-SCCHN), the role of anti-CTLA-4 remains uncertain. We evaluated whether escalated therapy targeting PD-1 and CTLA-4 is superior to docetaxel (DOC) in nivolumab-refractory patients (pts).